Skip to Content
Søg Menu

Late-Breaking from ASH22 – Zanubrutinib has Now Proven Superiority to Ibrutinib

The ALPINE study is the first study to demonstrate a superior Progression-Free Survival (PFS) and safety profile of zanubrutinib compared to ibrutinib in patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL).

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Increased Relative Risk of Cancer for Relatives to Patients with Myelodysplastic Neoplasms and Leukemia

/ Nikolaj Juul Nitschke / Kirsten Grønbæk
CancerLeukæmi

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL

ASH 2023: The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated CLL

/ BestPractice Nordic
ASH23CLL
Jeff P. Sharman

No Increased Risk of Ventricular Arrhythmias and Sudden Death with Acalabrutinib

/ Jeff P. Sharman
ASH23CLL Play the Video 1:45
Jeff P. Sharman

Acalabrutinib in Frontline CLL Treatment: Six-Year Results from the Elevate-TN Study

/ Jeff P. Sharman
ASH23CLL Play the Video 2:45

ASH 2023: ELEVATE-TN Study – 6-Year Follow-up of Acalabrutinib Efficacy in CLL

/ BestPractice Nordic
ASH23CLL
Peter Hillmen

New Standard of Care for Previously Untreated CLL

/ Peter Hillmen
ASH23CLL Play the Video 5:40

ASH 2023: CAPTIVATE Study – Ibrutinib-Venetoclax for CLL/SLL

/ BestPractice Nordic
ASH23CLL
Paolo Ghia

CAPTIVATE Study: CLL Combination Therapy of Ibrutinib and Venetoclax

/ Paolo Ghia
ASH23CLL Play the Video 4:30

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top